stockrowMaxCyte, Inc.
MXCT Healthcare Medical Devices
MaxCyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $33.0 million, down 14.5% from fiscal 2024.
- Revenue
- −14.5%
- EPS
- +33.3%
- Free cash flow
- +54.7%
Quarter to June 2026, against a year earlier
Follow MXCT
Alert me
MaxCyte, Inc. (MXCT) EV/Sales
As of 5 November 2026, MaxCyte, Inc. (MXCT) trades at a EV/Sales of 1.3×. Over the past ten years it has ranged from −0.8× (March 2026) to 48.1× (September 2021); the current reading is higher than 27% of that period. That is below the Medical Devices industry median of 2.7× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.0× | (72.72%) |
| FY2024 | 7.4× | (13.21%) |
| FY2023 | 8.5× | 26.85% |
| FY2022 | 6.7× | (66.07%) |
| FY2021 | 19.9× | 31.28% |
| FY2020 | 15.1× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.0× | — |
| Mar 2026 | −0.8× | — |
| Dec 2025 | 2.0× | 2.98% |
| Sep 2025 | 2.0× | (36.31%) |
| 22 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CATX Perspective Therapeutics, Inc. compare | −339× |
| RXST RxSight, Inc. compare | −0.4× |
| INGN Inogen, Inc compare | 0.2× |
| QTRX Quanterix Corporation compare | 0.3× |
| OWLT Owlet, Inc. compare | 0.9× |
| LUNG Pulmonx Corporation compare | 1.1× |
| MXCT MaxCyte, Inc. | 1.3× |
| STIM Neuronetics, Inc. compare | 1.5× |
| APYX Apyx Medical Corporation compare | 2.5× |
| Medical Devices industry median | 2.7× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)